Arcus Biosciences reported positive results from its ARC-7 study and has a strong cash position of $1.3 billion to fund operations into 2026. The company is advancing its pipeline with multiple Phase 3 trials planned.
Both anti-TIGIT domvanalimab-containing arms in the ARC-7 study continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone for first-line metastatic non-small cell lung cancer (NSCLC).
Arcus and Gilead are expanding their late-stage clinical program for domvanalimab, aiming to establish a best-in-class PD-1 + TIGIT antibody backbone and triplet regimens.
The third registrational Phase 3 study, STAR-121, will evaluate domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab with chemotherapy in first-line NSCLC PD-L1 all-comers, expected to initiate in 4Q 2022.
Arcus is well positioned to advance its programs with $1.3 billion in cash and cash equivalents, providing funding into 2026.
Arcus Biosciences is focused on advancing its clinical programs and expects several milestones in the near term.
Analyze how earnings announcements historically affect stock price performance